ストックスクリーナーアプリを入手
1.79
1.65%
-0.03
プレマーケット:
1.76
-0.03
-1.68%
前日終値:
$1.82
開ける：
$1.84
24時間の取引高:
3.71M
Relative Volume:
1.26
時価総額：
$188.48M
収益：
-
当期純損益:
$-37.34M
株価収益率:
-1.3162
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
-7.73%
1か月 パフォーマンス:
-4.28%
6か月 パフォーマンス:
+2.87%
1年 パフォーマンス:
+50.42%
1日の値動き範囲:
$1.73
$1.85
1週間の範囲:
$1.73
$2.12
52週間の値動き範囲:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
SLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.79 | 268.34M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdownWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Does SELLAS Life Sciences Group Inc. fit your quant trading modelJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
SELLAS to present SLS009 data for relapsed leukemia at ASH meeting - Investing.com Nigeria
SELLAS to present SLS009 data for relapsed leukemia at ASH meeting By Investing.com - Investing.com South Africa
SELLAS Life Sciences (NASDAQ: SLS) to present SLS009 with azacitidine and venetoclax in AML-MR at ASH 2025 - Stock Titan
SELLAS Life Sciences Group Inc. stock prediction for this weekLong Setup & Weekly High Return Stock Opportunities - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsJuly 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Should you wait for a breakout in SELLAS Life Sciences Group Inc.2025 Dividend Review & Daily Chart Pattern Signal Reports - newser.com
Can SELLAS Life Sciences Group Inc. stock sustain revenue growthJuly 2025 Reactions & Long-Term Growth Plans - newser.com
SELLAS Life Sciences Group Inc. stock outlook for YEAR2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Understanding SELLAS Life Sciences Group Inc.’s price movementPortfolio Update Report & Proven Capital Preservation Methods - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 2025Weekly Trade Summary & Reliable Intraday Trade Plans - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Trading Recap & AI Driven Price Predictions - newser.com
Using economic indicators to assess SELLAS Life Sciences Group Inc. potentialJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulation2025 Price Momentum & Reliable Volume Spike Trade Alerts - newser.com
What technical models suggest about SELLAS Life Sciences Group Inc.’s comeback2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is SELLAS Life Sciences Group Inc. stock attractive for retirement portfoliosMarket Risk Analysis & Growth Focused Entry Reports - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.35%
大文字化:
|
ボリューム (24 時間):